NEW YORK, Nov. 1 — Human Genome Sciences on Thursday announced that a monoclonal antibody product it developed has been approved by the US Food and Drug Administration to begin phase I trials, becoming the first drug candidate of its kind identified through genomics techniques to reach this stage.

The product, LymphoStat-B, will first be tested as a treatment for the autoimmune disease lupus. Clinical trials should begin by the new year, said company spokesperson Jerry Parrot. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.